Growth inhibition of Mycobacterium smegmatis by mycobacteriophage-derived enzymes

Enzyme and Microbial Technology

Volumn 63, Issue , 2014, Pages 1-6

  Grover, Navdeep ^a,b   Paskaleva, Elena E ^a,b   Mehta, Krunal K ^a,b   Dordick, Jonathan S ^a,b,c   Kane, Ravi S ^a,b  

^a Rensselaer Polytechnic Institute   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^c RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Bactericidal; LysB; Mycobacteriophage; Mycobacterium smegmatis; Phage derived lysins; Tuberculosis

Indexed keywords

BACTERIA; ENZYME INHIBITION; ESTERS; MASS SPECTROMETRY; PURIFICATION;

BACTERICIDAL; LYSB; MYCOBACTERIOPHAGE; MYCOBACTERIUM SMEGMATIS; TUBERCULOSIS;

ENZYME ACTIVITY;

BACTERIAL PROTEIN; ENDOLYSIN; ESTERASE; GALACTAN; MYCOLYLARABINOGALACTAN; PROTEINASE; RECOMBINANT PROTEIN; SURFACTANT;

AMINO ACID SEQUENCE; BACTERIOPHAGE; CELL WALL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; ENZYME SPECIFICITY; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; HYDROLYSIS; METABOLISM; MOLECULAR GENETICS; MYCOBACTERIUM SMEGMATIS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; BACTERIAL PROTEINS; BACTERIOPHAGES; CELL WALL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENDOPEPTIDASES; ESTERASES; GALACTANS; HYDROLYSIS; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM SMEGMATIS; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTRATE SPECIFICITY; SURFACE-ACTIVE AGENTS;

EID: 84901299234     PISSN: 01410229     EISSN: 18790909     Source Type: Journal    
DOI: 10.1016/j.enzmictec.2014.04.018     Document Type: Article

References (47)

1. Levin B.R., Bull J.J. Population and evolutionary dynamics of phage therapy. Nat Rev 2004, 2:166-173.
2. Singh A., Arutyunov D., Szymanski C.M., Evoy S. Bacteriophage based probes for pathogen detection. Analyst 2012, 137:3405-3421.
3. Ripp S. Bacteriophage-based pathogen detection. Adv Biochem Eng Biotechnol 2010, 118:65-83.
4. Ryan E.M., Alkawareek M.Y., Donnelly R.F., Gilmore B.F. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol Med Microbiol 2012, 65:395-398.
5. Barrow P.A., Soothill J.S. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of the potential. Trends Microbiol 1997, 5:268-271.
6. Smith H.W., Huggins R.B. Successful treatment of experimental E. coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982, 128:307-318.
7. Wang I.N., Smith D.L., Young R.H. The protein clocks of bacteriophage infections. Annu Rev Microbiol 2000, 54:799-825.
8. Young I., Wang I., Roof W.D. Phages will out: strategies of host cell lysis. Trends Microbiol 2000, 8:120-128.
9. Fischetti V.A. Phage antibacterials make a comeback. Nat Biotechnol 2001, 19:734-735.
10. Fischetti V.A. Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol 2005, 13:491-496.
11. Son B., Yun J., Lim J.-A., Shin H., Heu S., Ryu S. Characterization of LysB4, an endolysin from the Bacillus cereus-infecting bacteriophage B4. BMC Microbiol 2012, 12:1-9.
12. Lukacik P., Barnard T.J., Keller P.W., Chaturvedi K.S., Seddiki N., Fairman J.W., et al. Structural engineering of a phage lysin that targets Gram-negative pathogens. Proc Natl Acad Sci USA 2012, 109:1-6.
13. Fischetti V.A. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int J Med Microbiol 2010, 300:357-362.
14. Nelson D., Loomis L., Fischetti V.A. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 2001, 98:4107-4112.
15. Loeffler J.M., Nelson D., Fischetti V.A. Rapid killing of Streptococcus pneumonia with a bacteriophage cell wall hydrolase. Science 2001, 294:2170-2172.
16. Cheng Q., Nelson D., Zhu S., Fischetti V.A. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother 2005, 49:111-117.
17. Müller B., Borrell S., Rose G., Gagneux S. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet 2013, 29:160-169.
18. Mitnick C.D., McGee B., Peloquin C.A. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 2009, 10:381-401.
19. World Health Organization Update tubercluosis facts 2009.
20. Broxmeyer L., Sosnowska D., Miltner E., Chacón O., Wagner D., McGarvey J., et al. Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J Infect Dis 2002, 186:1155-1160.
21. Foley-Thomas E.M., Whipple D.L., Bermudez L.E., Barletta R.G. Phage infection, transfection and transformation of Mycobacterium avium complex and Mycobacterium paratuberculosis. Microbiology 1995, 141:1173-1181.
22. Danelishvili L., Young L.S., Bermudez L.E. In Vivo efficacy of phage therapy for Mycobacterium avium infection as delivered by a nonvirulent mycobacterium. Microb Drug Resist 2006, 12:1-6.
23. Catalão M.J., Gil F., Moniz-Pereira J., Pimentel M. The mycobacteriophage Ms6 encodes a chaperone-like protein involved in the endolysin delivery to the peptidoglycan. Mol Microbiol 2010, 77:672-686.
24. Payne K.M., Hatfull G.F. Mycobacteriophage endolysins: diverse and modular enzymes with multiple catalytic activities. PLoS ONE 2012, 7:1-14.
25. Gil F., Catalão M.J., Moniz-Pereira J., Leandro P., McNeil M.R., Pimentel M. The lytic cassette of mycobacteriophage Ms6 encodes an enzyme with lipolytic activity. Microbiology 2008, 154:1364-1371.
26. Gil F., Grzegorzewicz A.E., Catalão M.J., Vital J., McNeil M.R., Pimentel M. Mycobacteriophage Ms6 LysB specifically targets the outer membrane of Mycobacterium smegmatis. Microbiology 2010, 156:1497-1504.
27. Mahapatra S., Piechota C., Gil F., Yufang M., Huang H., Scherman M.S., et al. Mycobacteriophage Ms6 LysA: a peptidoglycan amidase and useful analytical tool. Appl Environ Microbiol 2013, 79:768-773.
28. Daffè M. The global architecture of the mycobacterial cell envelope. The mycobacterial cell envelope 2008, 3-11. American Society for Microbiology, Washington, DC. M. Daffè, J.-M. Reyrat (Eds.).
29. Daffè M., Draper P. The envelope layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol 1998, 39:131-203.
30. Bhamidi S., Scherman M.S., Rithner C.D., Prenni J.E., Chatterjee D., Khoo K.-H., et al. The identification and location of succinyl residues and the characterization of the interior arabinan region allow for a model of the complete primary structure of Mycobacterium tuberculosis mycolyl arabinogalactan. J Biol Chem 2008, 283:12992-13000.
31. Rybniker J., Kramme S., Small P.L. Host range of 14 mycobacteriophages in Mycobacterium ulcerans and seven other mycobacteria including Mycobacterium tuberculosis - application for identification and susceptibility testing. J Med Microbiol 2006, 55:37-42.
32. Mehta K.K., Paskaleva E.E., Azizi-Ghannad S., Ley D.J., Page M.A., Dordick J.S., et al. Characterization of AmiBA2446, a novel bacteriolytic enzyme active against Bacillus species. Appl Environ Microbiol 2013, 79:5899-5906.
33. Solanki K., Grover N., Downs P., Paskaleva E.E., Mehta K.K., Lee L., et al. Enzyme-based listericidal nanocomposites. Sci Rep 2013, 3:1-6.
34. Jiang Z., Higgins M.P., Whitehurst J., Kisich K.O., Voskuil M.I., Hodges R.S. Anti-tubercluosis activity of α-helical antimicrobial peptides: de novo designed l- and d-enantiomers versus l- and d-LL37. Protein Pept Lett 2011, 18:241-252.
35. Pangule P.C., Brooks S.J., Dinu C.Z., Bale S.S., Salmon S.L., Zhu G., et al. Antistaphylococcal nanocomposite films based on enzyme nanotube conjugates. ACS Nano 2010, 4:3993-4000.
36. Payne K., Sun Q., Sacchettini J., Hatfull G.F. Mycobacteriophage Lysin B is a novel mycolylarabinogalactan esterase. Mol Microbiol 2009, 73:367-381.
37. Delorme V., Dhouib R., Canaan S., Fotiadu F., Carrière F., Cavalier J.F. Effects of surfactants on lipase structure, activity, and inhibition. Pharm Res 2011, 28:1831-1842.
38. Diaz J.C., Cordova J., Baratti J., Carrière F., Abousalham A. Effect of nonionic surfactants on Rhizopus homothallicus lipase activity: a comparative kinetic study. Mol Biotechnol 2007, 35:205-214.
39. Peters G.H., Olsen O.H., Syendsen A., Wade R.C. Theoretical investigation of the dynamics of the active site lid in Rhizomucor miehei lipase. Biophys J 1996, 71:119-129.
40. Brocca S., Secundo F., Ossola M., Alberghina L., Carrea G., Lotti M. Sequence of the lid affects activity and specificity of Candida rugosa lipase isoenzymes. Protein Sci 2003, 12:2312-2319.
41. Chahiniana H., Sarda L. Distinction between esterases and lipases: comparative biochemical properties of sequence-related carboxylesterases. Protein Pept Lett 2009, 16(10):1149-1161.
42. Ojha A., Anand M., Bhatt A., Kremer L., Jacobs W.R., Hatfull G.F. GroEL1: a dedicated chaperone involved in mycolic acid biosynthesis during biofilm formation in mycobacteria. Cell December 2, 2005, 123(5):861-873.
43. Liu J., Barry C.E., Besra G.S., Nikaido H. Mycolic acid structure determines the fluidity of the mycobacterial cell wall. J Biol Chem 1996, 271:29545-29551.
44. Barkan D., Liu Z., Sacchettini J.C., Glickman M.S. Mycolic acid cyclopropanation is essential for viability, drug resistance, and cell wall integrity of Mycobacterium tuberculosis. Chem Biol 2009, 16:499-509.
45. Camacho L.R., Constant P., Raynaud C., Lanéelle M.-A., Triccas J.A., Gicquel B., et al. Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability barrier. J Biol Chem 2001, 276:19845-19854.
46. Teng R., Dick T. Isoniazid resistance of exponentially growing Mycobacterium smegmatis biofilm culture. FEMS Microbiol Lett 2003, 227:171-174.
47. Arora K., Whiteford D.C., Lau-Bonilla D., Davitt C.M., Dahl J.L. Inactivation of lsr2 results in a hypermotile phenotype in Mycobacterium smegmatis. J Bacteriol 2008, 190:4291-4300.